(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 January 2020 (23.01.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/016318 A1

(51) International Patent Classification:
A61K 38/48 (2006.01) *C12N 9/64* (2006.01)
A61K 39/12 (2006.01)

(21) International Application Number:
PCT/EP2019/069280

(22) International Filing Date:
17 July 2019 (17.07.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
18305971.6 17 July 2018 (17.07.2018) EP
62/768,731 16 November 2018 (16.11.2018) US

(71) Applicants: **INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)** [FR/FR]; 101, rue de Tolbiac, 75013 Paris (FR). **GENETHON** [FR/FR]; 1 bis, rue de l'Internationale, 91000 Evry (FR). **SORBONNE UNIVERSITÉ,** [FR/FR]; 21 rue de l'Ecole de Médecine, 75006 Paris (FR). **UNIVERSITÉ PARIS DESCARTES** [FR/FR]; 12, rue de l'Ecole de Médecine, 75006 Paris (FR). **UNIVERSITÉ PARIS DIDEROT - PARIS 7** [FR/FR]; 5, rue Thomas Mann, 75013 Paris (FR). **SPARK THERAPEUTICS, INC.** [US/US]; 3737 Market Street, Ste. 1300, Philadelphia, PA 19104 (US).

(72) Inventors: **LACROIX-DESMAZES, Sébastien**; INSERM UMR 1138, Centre de Recherche des Cordeliers, 15 rue de l'Ecole de Médecine, 75006 Paris (FR). **MINGOZZI, Federico**; 604 Saint Andrews Road, Philadelphia, PA 19118 (US). **DIMITROV, Jordan**; INSERM U1138, 15 rue de l'Ecole de Médecine, 75006 PARIS (FR). **LEBORGNE, Christian**; IMF (Immunologie et Maladies du Foie), 1 bis rue de l'Internationale, 91000 Evry (FR). **ARMOUR, Sean**; 604 Saint Andrews Road, Philadelphia, PA 19118 (US).

(74) Agent: **INSERM TRANSFERT**; 7 rue Watt, 75013 Paris (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2020/016318 A1

(54) Title: COMPOSITIONS AND METHODS FOR INCREASING OR ENHANCING TRANSDUCTION OF GENE THERAPY VECTORS AND FOR REMOVING OR REDUCING IMMUNOGLOBULINS

(57) Abstract: Disclosed herein are methods for treating patients that may develop or already have pre- existing gene therapy neutralizing antibodies by administering a protease that cleaves peptide bonds present in immunoglobulins or by administering a glycosidase that cleaves carbohydrate residues present on immunoglobulins, or other similar enzymatic cleavage of immunoglobulins in vivo. Also disclosed are methods for utilizing IdeS and other immunoglobulin G-degrading enzyme polypeptides for gene therapy treatment of a disease in a patient in need thereof.